ISTO Biologics, Inc., was acquired by Thompson Street Capital Partners in June 2016 but went on to institute a working relationship with Zimmer an important player in the orthopaedic reconstructive implants and fracture management products but its first foray into orthobiolgics. ISTO Biologics - the entity created when Arteriocyte and Isto Technol0gies - both SBIR involved - merged in 2016 - is an orthobiologics company developing diffentiated products for spinal therapy, sports medicine, and trauma. The firm develops implantable biomaterials for the repair and regeneration of musculoskeletal tissues, such as bone and cartilage - being developed to grow human cartilage tissue from chondrocytes derived from human donors. This laboratory-grown cartilage is intended for surgical implantation to repair or replace injured or diseased cartilage in the knee or other joints which has, until now, been unreplaceable. ISTO is also developing a cell-based regenerative therapy for spinal discs. The firm offers InQu, a resorbable bone graft extender and substitute; NuQu, a cell-based injectable therapy for disc regeneration; and DeNovo ET, an engineered cartilage implant for the repair and regeneration of knee cartilage. Two of its products are currently undergoing clinical trials.